UNLABELLED: Current treatments for postmenopausal osteoporosis suffer from side effects. Safe and natural milk proteins, ribonuclease, and lactoferrin promote formation of new capillaries and bone formation. A ribonuclease-enriched lactoferrin supplement studied here, demonstrates significant reduction in resorption and increase in formation, towards restoring the balance of bone turnover within 6 months. INTRODUCTION: Osteoporosis, a major health issue among postmenopausal women, causes increased bone resorption and reduced bone formation. A reduction in angiogenesis could also contribute to this imbalance. Current treatments such as hormone replacement therapy and bisphosphonates have drawbacks of severe side effects. Milk ribonuclease (RNase) is known to promote angiogenesis and lactoferrin (LF) to stimulate bone formation by osteoblasts. We examine the effect of ribonuclease-enriched lactoferrin supplement on the bone health of postmenopausal women. METHODS: A total of 38 healthy, postmenopausal women, aged 45 to 60 years were randomized into placebo or RNAse-enriched-LF (R-ELF) supplement groups. The bone health status was monitored by assessing bone resorption markers, serum N-telopeptides (NTx), and urine deoxypyridinoline (Dpd) crosslinks and serum bone formation markers, bone-specific alkaline phosphatase (BAP), and osteocalcin (OC). RESULTS: R-ELF supplementation demonstrated a decrease in urine Dpd levels by 14% (19% increase for placebo) and serum NTx maintained at 24% of the baseline (41% for placebo), while serum BAP and OC levels showed a 45% and 16% elevation (25% and 5% for placebo). CONCLUSIONS: R-ELF supplementation demonstrated a statistically significant reduction in bone resorption and increase in osteoblastic bone formation, to restore the balance of bone turnover within a short period.
RCT Entities:
UNLABELLED: Current treatments for postmenopausal osteoporosis suffer from side effects. Safe and natural milk proteins, ribonuclease, and lactoferrin promote formation of new capillaries and bone formation. A ribonuclease-enriched lactoferrin supplement studied here, demonstrates significant reduction in resorption and increase in formation, towards restoring the balance of bone turnover within 6 months. INTRODUCTION:Osteoporosis, a major health issue among postmenopausal women, causes increased bone resorption and reduced bone formation. A reduction in angiogenesis could also contribute to this imbalance. Current treatments such as hormone replacement therapy and bisphosphonates have drawbacks of severe side effects. Milk ribonuclease (RNase) is known to promote angiogenesis and lactoferrin (LF) to stimulate bone formation by osteoblasts. We examine the effect of ribonuclease-enriched lactoferrin supplement on the bone health of postmenopausal women. METHODS: A total of 38 healthy, postmenopausal women, aged 45 to 60 years were randomized into placebo or RNAse-enriched-LF (R-ELF) supplement groups. The bone health status was monitored by assessing bone resorption markers, serum N-telopeptides (NTx), and urine deoxypyridinoline (Dpd) crosslinks and serum bone formation markers, bone-specific alkaline phosphatase (BAP), and osteocalcin (OC). RESULTS: R-ELF supplementation demonstrated a decrease in urine Dpd levels by 14% (19% increase for placebo) and serum NTx maintained at 24% of the baseline (41% for placebo), while serum BAP and OC levels showed a 45% and 16% elevation (25% and 5% for placebo). CONCLUSIONS: R-ELF supplementation demonstrated a statistically significant reduction in bone resorption and increase in osteoblastic bone formation, to restore the balance of bone turnover within a short period.
Authors: S Aoe; Y Toba; J Yamamura; H Kawakami; M Yahiro; M Kumegawa; A Itabashi; Y Takada Journal: Biosci Biotechnol Biochem Date: 2001-04 Impact factor: 2.043
Authors: R Eastell; N Mallinak; S Weiss; M Ettinger; M Pettinger; D Cain; K Fressland; C Chesnut Journal: J Bone Miner Res Date: 2000-03 Impact factor: 6.741
Authors: Marc C Hochberg; Susan Greenspan; Richard D Wasnich; Paul Miller; Desmond E Thompson; Philip D Ross Journal: J Clin Endocrinol Metab Date: 2002-04 Impact factor: 5.958
Authors: B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings Journal: JAMA Date: 1999-08-18 Impact factor: 56.272
Authors: John L Vahle; Masahiko Sato; Gerald G Long; Jamie K Young; Paul C Francis; Jeffery A Engelhardt; Michael S Westmore; Yanfei Linda; James B Nold Journal: Toxicol Pathol Date: 2002 May-Jun Impact factor: 1.902
Authors: Satish Bharadwaj; Tezus A G Naidu; Guru V Betageri; Nemani V Prasadarao; A Satyanarayan Naidu Journal: Inflamm Res Date: 2010-05-15 Impact factor: 4.575
Authors: R Filip; S Possemiers; A Heyerick; I Pinheiro; G Raszewski; M-J Davicco; V Coxam Journal: J Nutr Health Aging Date: 2015-01 Impact factor: 4.075
Authors: Lana Sarita de Souza de Oliveira; Aurigena Antunes de Araújo; Raimundo Fernandes de Araújo Júnior; Carlos Augusto Galvão Barboza; Boniek Castillo Dutra Borges; José Sandro Pereira da Silva Journal: Int J Exp Pathol Date: 2017-05-29 Impact factor: 1.925
Authors: Hanie Kheiridoost-Langaroodi; Seyed Kazem Shakouri; Mahdi Amirpour; Amir Mehdi Iranshahi; Azizeh Farshbaf-Khalili Journal: J Family Reprod Health Date: 2022-03